Jacob Chacko

Jacob Chacko, listed as chief executive, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Oric Pharmaceuticals, Inc., 4D Molecular Therapeutics, Inc. and Ignyta, Inc. In total, 26 filings cover trades dated from 7 January 2016 to 15 December 2025.

The open-market side counts 2 purchases for €2.0M alongside 18 sales for €3.7M. The net balance comes to €1.7M on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 1 share grant and 5 option exercises. Since January 2025: no purchases and 3 sales on the market.

On 17 December 2025 came the latest disclosure, an option exercise in Oric Pharmaceuticals, Inc. The most recent open-market purchase was published on 13 May 2022, 1,619 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.